Sloy Dahl & Holst’s CRISPR Therapeutics CRSP Stock Holding History

Sloy Dahl & Holst’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,353	Closed	-$460K	–	88
2023 Q4	$460K	Buy	7,353 +723	+11%	+$40K	0.09%	52
2023 Q3	$301K	Hold	6,630	–	–	0.07%	63
2023 Q2	$372K	Hold	6,630	–	–	0.07%	54
2023 Q1	$300K	Hold	6,630	–	–	0.07%	50
2022 Q4	$270K	Hold	6,630	–	–	0.09%	53
2022 Q3	$433K	Hold	6,630	–	–	0.09%	42
2022 Q2	$403K	Hold	6,630	–	–	0.1%	45
2022 Q1	$416K	Buy	+6,630	New	+$416K	0.07%	46
2021 Q3	–	Sell	-33,376	Closed	-$5.4M	–	93
2021 Q2	$5.4M	Buy	33,376 +6,213	+23%	+$756K	0.73%	16
2021 Q1	$3.31M	Buy	+27,163	New	+$4.1M	0.47%	17

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sloy Dahl & Holst's CRSP Position: Q1 2024 in Review

Sloy Dahl & Holst sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 7,353 shares — an estimated $460K sold.

Sloy Dahl & Holst first reported a position in CRSP in Q1 2021 and held it in 10 quarters. The position peaked at $5.4M in Q2 2021. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

Sloy Dahl & Holst reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
Sloy Dahl & Holst sold 7,353 CRISPR Therapeutics shares in Q1 2024, an estimated $460K.
Sloy Dahl & Holst first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 10 quarters.
Sloy Dahl & Holst's CRISPR Therapeutics position peaked at $5.4M in Q2 2021.
484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on Sloy Dahl & Holst's 13F filing for Q1 2024, filed 19 Apr 2024.